BamSEC and AlphaSense Join Forces
Learn More

Dicerna Pharmaceuticals Inc

Formerly NASDAQ: DRNA
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.9
from 10-Q 47 pages Dicerna Pharmaceuticals, Inc. $200,000,000 Common Stock Sales Agreement
12/34/56
EX-10.8
from 10-Q 1 page Amendment No. 1 to Employment Agreement
12/34/56
EX-10.7
from 10-Q 1 page Amendment No. 1 to Employment Agreement
12/34/56
EX-10.6
from 10-Q 1 page Amendment No. 1 to Employment Agreement
12/34/56
EX-10.5
from 10-Q 1 page Amendment No. 1 to Employment Agreement
12/34/56
EX-10.4
from 10-Q 1 page Amendment No. 1 to Employment Agreement
12/34/56
EX-10.3
from 10-Q 1 page Amendment No. 1 to Employment Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Amendment No. 1 to Transition and Separation Agreement
12/34/56
EX-10.1
from 10-Q 48 pages Royalty Purchase Agreement by and Between Dicerna Pharmaceuticals, Inc. and Rpi 2019 Intermediate Finance Trust Dated as of April 8, 2021
12/34/56
EX-10.4
from 10-Q 5 pages Dicerna Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.3
from 10-Q 5 pages Dicerna Pharmaceuticals, Inc. Amended and Restated 2014 Performance Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Employment Agreement Employment Agreement (“Agreement”) Made This 15th Day of September 2020 (The “Effective Date”) Between Dicerna Pharmaceuticals, Inc., a Delaware Corporation (“Company”), on the One Hand and Ling Zeng (The “Executive”) on the Other Hand. Whereas, the Company Desires to Employ the Executive and the Executive Desires to Be Employed by the Company, on Terms Set Forth Herein; Now, Therefore, in Consideration of the Mutual Agreements Set Forth Herein, the Parties Agree as Follows
12/34/56
EX-10.1
from 10-Q 9 pages Employment Agreement
12/34/56
EX-10.7
from 10-Q 15 pages Second Amendment to Lease Agreement
12/34/56
EX-10.6
from 10-Q 26 pages 75 Hayden Avenue Lexington, Massachusetts (The “Building”) First Amendment
12/34/56
EX-10.5
from 10-Q 5 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed. Second Amendment to Collaboration and License Agreement
12/34/56
EX-10.4
from 10-Q 2 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed. First Amendment to Collaboration and License Agreement
12/34/56
EX-10.3
from 10-Q 49 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed. Patent Cross-License Agreement Between Dicerna Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. April 3, 2020
12/34/56
EX-10.2
from 10-Q 92 pages Collaboration and License Agreement
12/34/56
EX-10.1
from 10-Q 10 pages Employment Agreement
12/34/56